Affiliated with a Castle Connolly Top Hospital
Who is Dr. Greenberg, Hematologist in Stanford, CA?
Dr. Peter Greenberg, MD is a Hematologist, who primarily practices in Stanford, CA with 1 additional practice location. He is board certified. Dr. Greenberg completed his residency at Barnes Hospital. Dr. Greenberg is fluent in English and Spanish, and is currently seeing new patients. Dr. Greenberg’s practice accepts Kaiser Permanente, Medicaid, Medicare and other major insurance plans. To book an appointment or to confirm insurance options, please call Dr. Greenberg’s office at (650) 723-4000.
Where did Dr. Greenberg go to medical school and complete their residency?
Fellowship: Stanford University School of Medicine CA | Stanford University School of Medicine,Stanford, Ca, United States
Residency: Barnes Hospital | Barnes-Jewish Hospital | Stanford University Medical Center
Is Dr. Greenberg board certified as a Hematologist?
Yes, Dr. Peter Greenberg, MD is board certified by the American Board of Internal Medicine , American Board of Internal Medicine since 1976, American Board of Internal Medicine since 1970
What languages does Dr. Greenberg speak?
Dr. Greenberg and their clinical team can communicate with patients in the following languages:
English
Spanish
What conditions does a Hematologist like Dr. Greenberg typically treat?
As a Hematologist, Dr. Greenberg diagnoses, treats, and manages a wide range of conditions. This condition information is derived from anonymized insurance claims and highlights the medical conditions most commonly treated by Dr. Greenberg. It provides insight into the doctor’s areas of experience and expertise based on real-world patient encounters from the past two years, updated quarterly. Learn more about our claims-based healthcare methodology.
Also known as:
- Myelodysplastic Syndrome
- Myelodysplastic Syndromes
- Myelodysplastic Syndromes Treatment (PDQ®)
- Myelodysplastic Syndromes Treatment (PDQ)
- MDS
- Preleukemia
- Bone marrow failure disorder
- Bone Marrow Failure Syndrome
ICD-10 Codes:
- D469: Myelodysplastic syndrome, unspecified
- D46Z: Other myelodysplastic syndromes
Also known as:
- Chronic Myelomonocytic Leukemia
- Acute Myeloid Leukemia
- Chronic Myeloid Leukemia
- Myelodysplastic/Myeloproliferative Neoplasms Treatment (PDQ®)
- CMML
- Myelomonocytic Leukemia
- AML Leukemia
- Acute Myeloblastic Leukemia
- Acute Myelogenous Leukemia
ICD-10 Codes:
- C9310: Chronic myelomonocytic leukemia not having achieved remission
- C9200: Acute myeloblastic leukemia, not having achieved remission
What procedures does a Hematologist like Dr. Greenberg typically perform?
As a Hematologist, Dr. Greenberg performs a variety of medical procedures. This procedure information is derived from anonymized insurance claims and highlights the medical procedures most commonly performed by Dr. Greenberg. It provides insight into the doctor’s areas of experience and expertise based on real-world patient encounters from the past two years, updated quarterly. Learn more about our claims-based healthcare methodology.
Also known as:
- Blood Transfusion
- Blood Transfusion and Donation
- Blood product transfusion
- Red blood cell transfusion
- Plasma transfusion
CPT Codes:
- 36430: Transfusion, blood or blood components
Also known as:
- Bone Marrow Biopsy and Aspiration
- Biopsy
- Bone Marrow Tests
- Bone Marrow Exam
- Bone Marrow Sample Collection
- Diagnostic Bone Marrow Procedure
CPT Codes:
- 38222: Diagnostic bone marrow; biopsy(ies) and aspiration(s)
Does Dr. Greenberg accept my insurance?
Dr. Greenberg accepts most major insurance plans. Important: Please call our office at (650) 723-4000 before your appointment to verify that your specific plan and network are accepted.
What insurance plans does Dr. Greenberg accept in Stanford, CA?
Dr. Greenberg in Stanford, CA accepts plans from many carriers. While this list is updated regularly, it is not a guarantee of coverage.
Top Insurances
Alignment Healthcare
All Other Third Party
Blue Shield of California
Cigna Group
CVS Health (formerly Aetna)
Elevance Health Inc. (formerly Anthem)
Medicare
UMR Administered Payer
UnitedHealth Group
Unknown
View All Insurances
Where is Dr. Greenberg's office located?
Recognitions
Awards
International Prize for outstanding research in myelodysplastic syndro
Publications
Role of Reduced-Intensity Conditioning Allogeneic Hematopoietic Stem
, 2013
Hematopoietic stem cell and progenitor cell mechanisms in myelodysplastic syndromes
, 2013
Risk of Therapy-Related Secondary Leukemia in Hodgkin Lymphoma
, 2013
The multifaceted ture of myelodysplastic syndromes: clinical, molecular
, 2013
Reduced rR expression and increased rD promoter methylation in CD34
, 2012
Revised Intertiol Prognostic Scoring System for Myelodysplastic Syndromes
, 2012
Molecular and genetic features of myelodysplastic syndromes
, 2012
Persol Omics Profiling Reveals Dymic Molecular and Medical Phenotypes
, 2012
Myelodysplastic Syndromes: Dissecting the Heterogeneity
, 2011
Myelodysplastic Syndromes
, 2011
Current therapeutic approaches for patients with myelodysplastic syndromes
, 2010
A phase II intra-patient dose
, 2009
NCCN Task Force Report: Transfusion and Iron Overload in Patients with Myelodysplastic Syndromes
, 2009
Myelodysplastic syndromes.
, 2008
The costs of drugs used to treat myelodyspl
, 2008
Intertiol MDS Risk Alysis Workshop (IMRAW)
Relative response of patients with myelodysplastic syndromes
, 2008
Phase II Study of Lelidomide in Transfusion-Dependent
, 2008
Myelodysplastic Syndromes
, 2007
Hematologic and cytogenetic response to lelidomide in myelodysplastic syndrome with chromosome 5q
, 2006
Myelodysplastic syndromes clinical practice guidelines in oncology.
, 2006
Myelodysplastic syndromes: iron overload consequences and current chelating therapies.
, 2006
Clinical application and proposal for modification of the Intertiol Working Group
, 2006
Magement of patients with higher risk myelodysplastic syndromes
, 2005
Mitoxantrone, etoposide
, 2004
A Decision Alysis of Allogeneic Bone Marrow Transplantation for the Myelodysplastic Syndromes
, 2004
Novel biospecific agents for the treatment of myelodysplastic syndromes.
, 2003
Treatment of myelodysplastic syndrome with agents interfering with inhibitory cytokines
, 2001
Implications of pathogenetic and prognostic features for magement of myelodysplastic syndromes
, 2001
Apoptosis and its role in the myelodysplastic syndromes
, 1998
Intertiol scoring system for evaluating prognosis in myelodysplastic syndromes
, 1997
Maintence treatment of the anemia of myelodyspl
, 1996
Biologic and clinical implications of marrow culture studies in the myelodysplastic syndromes
, 1996
Maintence treatment of the anemia of myelodysplastic syndromes with recombint human G
, 1996
TREATMENT OF THE ANEMIA OF MYELODYSPLASTIC SYNDROMES USING RECOMBINT HUMAN GRANULOCYTE-COLONY
, 1993
INVITRO MARROW CULTURE STUDIES IN THE MYELODYSPLASTIC SYNDROMES
, 1992
TREATMENT OF MYELODYSPLASTIC SYNDROMES WITH HEMATOPOIETIC GROWTH-FACTORS
, 1992
FUNCTIOL INTERACTIONS BETWEEN COLONY
, 1990
EFFECTS OF CSFS IN PRELEUKEMIA
, 1990
MAINTENCE TREATMENT OF PATIENTS WITH MYELODYSPLASTIC SYNDROMES USING RECOMBINT HUMAN GRANULOCYTE
, 1990
BONE-MARROW CELL MODULATION AND INHIBITION OF MYELOPOIESIS BY LARGE GRANULAR LYMPHOCYTES AND TURAL
, 1990
EFFECTS OF RECOMBINT HUMAN GRANULOCYTE COLONY STIMULATING FACTOR AND GRANULOCYTE
, 1990
EFFECTS OF PROLONGED TREATMENT OF MYELODYSPLASTIC SYNDROMES WITH RECOMBINT HUMAN GRANULOCYTE COLONY
, 1990
TREATMENT OF MYELODYSPLASTIC SYNDROMES WITH RECOMBINT HUMAN GRANULOCYTE COLONY-STIMULATING FACTOR
, 1989
SELECTIVE GENERATION OF ERYTHROID BURST PROMOTING ACTIVITY BY RECOMBINT INTERLEUKIN
, 1988
RECEPTOR-BINDING AND MITOGENIC EFFECTS OF INSULIN AND INSULIN
, 1987
BIOLOGIC TURE OF THE MYELODYSPLASTIC SYNDROMES
, 1987
Role of Reduced-Intensity Conditioning Allogeneic Hematopoietic Stem
, 2013
Hematopoietic stem cell and progenitor cell mechanisms in myelodysplastic syndromes
, 2013
Risk of Therapy-Related Secondary Leukemia in Hodgkin Lymphoma
, 2013
Specific plasma autoantibody reactivity in myelodysplastic syndromes
, 2013
The multifaceted nature of myelodysplastic syndromes: clinical, molecular
, 2013
Reduced rRNA expression and increased rDNA promoter methylation in CD34
, 2012
Revised International Prognostic Scoring System for Myelodysplastic Syndromes
, 2012
Molecular and genetic features of myelodysplastic syndromes
, 2012
Personal Omics Profiling Reveals Dynamic Molecular and Medical Phenotypes
, 2012
Distinctive contact between CD34+ hematopoietic progenitors
, 2012
Treatment of higher risk myelodyspl
, 2012
Myelodysplastic Syndromes: Dissecting the Heterogeneity
, 2011
Myelodysplastic Syndromes
, 2011
Prospective assessment of effects on iron
, 2010
Current therapeutic approaches for patients with myelodysplastic syndromes
, 2010
Relationship of differential gene expression profiles in CD34
, 2009
Treatment of myelodysplastic syndrome patients with erythropoietin with or without granulocyte
, 2009
A phase II intra-patient dose
, 2009
NCCN Task Force Report: Transfusion and Iron Overload in Patients with Myelodysplastic Syndromes
, 2009
Myelodysplastic syndromes.
, 2008
The costs of drugs used to treat myelodyspl
, 2008
International MDS Risk Analysis Workshop (IMRAW)
Predictive factors of response
, 2008
Factors affecting response
, 2008
Relative response of patients with myelodysplastic syndromes
, 2008
Phase II Study of Lenalidomide in Transfusion-Dependent
, 2008
Myelodysplastic Syndromes
, 2007
Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes
, 2007
Hematologic and cytogenetic response to lenalidomide in myelodysplastic syndrome with chromosome 5q
, 2006
Myelodysplastic syndromes clinical practice guidelines in oncology.
, 2006
A phase II study of the farnesyltransferase inhibitor tipifarnib
, 2006
Myelodysplastic Syndromes: Clinical and Biological Advances
Myelodysplastic syndromes: iron overload consequences and current chelating therapies.
, 2006
Clinical application and proposal for modification of the International Working Group
, 2006
Management of patients with higher risk myelodysplastic syndromes
, 2005
Mitoxantrone, etoposide
, 2004
A Decision Analysis of Allogeneic Bone Marrow Transplantation for the Myelodysplastic Syndromes
, 2004
Comparison of interphase FISH and metaphase cytogenetics to study myelodysplastic syndrome
, 2003
Novel biospecific agents for the treatment of myelodysplastic syndromes.
, 2003
Myelodysplastic syndromes.
, 2002
Treatment of myelodysplastic syndrome with agents interfering with inhibitory cytokines
, 2001
Implications of pathogenetic and prognostic features for management of myelodysplastic syndromes
, 2001
The Myelodysplastic Syndromes , .
, 2000
Prognostic scoring systems for risk assessment in myelodysplastic syndromes.
, 1999
Apoptosis and its role in the myelodysplastic syndromes
, 1998
Bcl-2 expression by myeloid precursors in myelodysplastic syndromes
, 1998
Risk factors and their relationship to prognosis in myelodysplastic syndromes
, 1998
NCCN Practice Guidelines for Myelodysplastic Syndromes
, 1998
International scoring system for evaluating prognosis in myelodysplastic syndromes
, 1997
Altered oncoprotein expression and apoptosis in myelodysplastic syndrome marrow cells
, 1996
GM-CSF accelerates neutrophil recovery after autologous hematopoietic stem cell transplantation
, 1996
Maintenance treatment of the anemia of myelodyspl
, 1996
Biologic and clinical implications of marrow culture studies in the myelodysplastic syndromes
, 1996
Maintenance treatment of the anemia of myelodysplastic syndromes with recombinant human G
, 1996
ENRICHMENT OF BONE-MARROW AND BLOOD PROGENITOR (CD34(+)) CELLS BY DENSITY GRADIENTS WITH SUFFICIENT
, 1995
MODULATION OF APOPTOSIS IN HUMAN MYELOID LEUKEMIC-CELLS BY GM-CSF
, 1995
EFFECTS OF GRANULOCYTE-COLONY
, 1995
TREATMENT OF THE ANEMIA OF MYELODYSPLASTIC SYNDROMES USING RECOMBINANT HUMAN GRANULOCYTE-COLONY
, 1993
T-CELL SUBSETS AND SUPPRESSOR CELLS IN HUMAN BONE-MARROW
, 1992
INVITRO MARROW CULTURE STUDIES IN THE MYELODYSPLASTIC SYNDROMES
, 1992
TREATMENT OF MYELODYSPLASTIC SYNDROMES WITH HEMATOPOIETIC GROWTH-FACTORS
, 1992
Programmed cell death (apoptosis) as a mechanism for regulating haematopoietic cell population size
TREATMENT OF MYELODYSPLASTIC SYNDROMES
, 1991
EFFECTS OF INSULIN-LIKE GROWTH-FACTORS ON HEMATOPOIESIS
, 1991
FUNCTIONAL INTERACTIONS BETWEEN COLONY
, 1990
IMPACT OF MARROW CYTOGENETICS AND MORPHOLOGY ON INVITRO HEMATOPOIESIS IN THE MYELODYSPLASTIC
, 1990
EFFECTS OF CSFS IN PRELEUKEMIA
, 1990
MAINTENANCE TREATMENT OF PATIENTS WITH MYELODYSPLASTIC SYNDROMES USING RECOMBINANT HUMAN
, 1990
BONE-MARROW CELL MODULATION AND INHIBITION OF MYELOPOIESIS BY LARGE GRANULAR LYMPHOCYTES AND
, 1990
EFFECTS OF RECOMBINANT HUMAN GRANULOCYTE COLONY STIMULATING FACTOR AND GRANULOCYTE
, 1990
HEMATOPOIETIC PROGENITOR-CELL EXPRESSION OF THE H-CAM (CD44) HOMING-ASSOCIATED ADHESION MOLECULE
, 1990
EFFECTS OF PROLONGED TREATMENT OF MYELODYSPLASTIC SYNDROMES WITH RECOMBINANT HUMAN GRANULOCYTE
, 1990
TREATMENT OF MYELODYSPLASTIC SYNDROMES WITH RECOMBINANT HUMAN GRANULOCYTE COLONY
, 1989
SELECTIVE GENERATION OF ERYTHROID BURST PROMOTING ACTIVITY BY RECOMBINANT INTERLEUKIN
, 1988
RECEPTOR-BINDING AND MITOGENIC EFFECTS OF INSULIN AND INSULIN
, 1987
BIOLOGIC NATURE OF THE MYELODYSPLASTIC SYNDROMES
, 1987
Granulopoiesis in acute myeloid leukemia and preleukemia
, 1971
What is Dr. Greenberg's NPI number?An National Provider Identifier (NPI) is a unique ID number that identifies doctors and healthcare providers nationwide.
Dr. Greenberg's National Provider Identifier (NPI) number is 1912033978.
What common questions do patients ask about Dr. Greenberg?
Here are answers to patients Frequently Asked Questions (FAQ’s) about Dr. Greenberg
What is Dr. Peter Greenberg's specialty?
Dr. Greenberg is a Hematologist near Stanford, CA.
What does a Hematologist do?
An internist with advanced training specializing in disorders of the blood, spleen, and lymphatic system. This specialist manages conditions such as anemia, clotting disorders, sickle cell disease, hemophilia, leukemia, and lymphoma.
Is this Dr. Peter Greenberg affiliated with a ranked Castle Connolly Top Hospital?
Yes, Dr. Greenberg is affiliated with Stanford Health Care - Stanford Hospital which is a Castle Connolly Top Hospital. Castle Connolly Top Hospitals are healthcare institutions recognized for their excellence in specific medical procedures and overall patient care. They are identified through a rigorous peer nomination process, evaluating factors like patient outcomes, quality of care, and expertise. The list recognizes hospitals that excel in 20 or more specific medical procedures, representing the top 25% nationwide. Castle Connolly Top Hospitals
When to see a Hematologist?: Guides for symptoms, conditions, and treatments
Understand your symptoms and know when it’s time to see a Hematologist. Explore insights from trusted medical experts on EverydayHealth.com, where you'll find the most relevant content and helpful condition guides for up-to date information about symptoms, causes, diagnosis, treatment and more. See all our health guides to find trusted information on medical conditions from our experts at Everyday Health.
Is Peter Greenberg accepting new patients in Stanford, CA?
Yes, Dr. Peter Greenberg is accepting new patients at this time.
Does Dr. Peter Greenberg offer online booking?
Please contact Dr. Greenberg's office at (650) 723-4000 for information about online booking, telehealth, or to schedule an appointment.
How can I make an appointment with Peter Greenberg?
Please contact Dr. Greenberg's office at (650) 723-4000 for information regarding telehealth appointment availability or for scheduling assistance.
Which board certifications does Dr. Peter Greenberg have?
Dr. Peter Greenberg is certified by the American Board of Internal Medicine.
Other Hematologist Near Stanford, CA
Medical Oncologist
Accepting patientsMedical Oncologist
Accepting patientsMedical Oncologist
Accepting patients